688278.SH
特宝生物
SSE · Healthcare · Biotechnology · CN
CNY 59.47
−3.89%Sep 1, 2026, 08:41 UTC
Amoytop Biotech disclosed that as of August 31, 2026, its second buyback plan of 2026 had repurchased 7,381,464 shares, representing 1.81% of total share capital, for a cumulative amount of 407 million yuan, with the buyback price ranging from 52.62 to 57.20 yuan per share.
Source:Aug 18, 2026, 11:08 UTC
Amoytop Biotech announced its 2026 first-half results: net profit of 477 million yuan, up 11.37% year-on-year.
Source:Jul 6, 2026, 20:05 UTC
Aligos Therapeutics received a $25M upfront payment from an exclusive license deal with Xiamen Amoytop Biotech for pevifoscorvir sodium in Greater China for chronic hepatitis B virus infection.
Source: